Maria Incer Obando, MD
Endocrinology, Diabetes & Metabolism · Belle Chasse, LANPI 1194777078
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,187 of the $7,524 with a category attached, or 82.2%. It is spread thinly across 31 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,409 and has fallen 53.1% since, to $1,129 in 2025.
Across 250 payments — averaging $30.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cambridge Interventional LLC$1K
- Amgen$838
- Novo Nordisk$780
- Boehringer Ingelheim$449
- Esperion Therapeutics, Inc.$430
- Dexcom, Inc.$380
- plus $3K from 25 others
What the payments were for
- Food & beverage$6,18782%
- Education$1,33718%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cambridge Interventional LLC | 2 | $1,313 |
| Amgen(2 entities) | 29 | $838 |
| Novo Nordisk | 47 | $780 |
| Boehringer Ingelheim | 22 | $449 |
| Esperion Therapeutics, Inc. | 8 | $430 |
| Dexcom, Inc. | 13 | $380 |
| Medtronic | 18 | $366 |
| Xeris Pharmaceuticals, Inc. | 14 | $281 |
| Ascendis Pharma Endocrinology Inc | 4 | $247 |
| Corcept Therapeutics | 8 | $243 |
| Lilly USA, LLC | 12 | $220 |
| AbbVie | 12 | $216 |
| Abbott | 5 | $202 |
| Amneal Pharmaceuticals LLC | 13 | $156 |
| Merck | 10 | $156 |
| Bayer | 8 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $146 |
| AstraZeneca(2 entities) | 2 | $139 |
| Johnson & Johnson | 1 | $125 |
| Shire North American Group Inc | 1 | $121 |
| Sanofi-aventis U.S. LLC | 6 | $120 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Mannkind Corporation | 1 | $99 |
| BETA Bionics, Inc. | 3 | $65 |
| Recordati_rare_diseases_inc. | 2 | $44 |
| Novartis | 2 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| GRT US Holding, Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Nevro Corp. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRF$1,313
- NEXLIZET$345
- NEXLETOL$345
- XARELTO$270
- Repatha$247
- FreeStyle Libre$128
- EVENITY$125
- ULTOMIRIS$124
- NATPARA (PARATHYROID HORMONE)$121
- DEXCOM G6 TRANSMITTER$108
- LifeVest$100
How this compares
$7,524 in reported general payments places this provider in the 65th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 14 | $702,747 |
| OzempicSemaglutide | 89 | $93,278 |
| JardianceEmpagliflozin | 62 | $54,202 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 16 | $38,855 |
| MounjaroTirzepatide | 31 | $32,829 |
| TymlosAbaloparatide | 11 | $28,450 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $22,788 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,496 |
| Omega-3 Acid Ethyl Esters | 16 | $1,383 |
| Potassium Chloride | 77 | $1,262 |
| Levothyroxine Sodium | 178 | $1,246 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 13 | $849 |
| Alendronate Sodium | 162 | $677 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $669 |
| Ibandronate Sodium | 21 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $243 | $702,74714 claims |
| Novo NordiskOzempic | $780 | $93,27889 claims |
| Boehringer IngelheimJardiance | $449 | $54,20262 claims |
| AmgenEvenity (2 Syringes) | $838 | $38,85516 claims |
| Lilly USA, LLCMounjaro | $220 | $32,82931 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $120 | $22,78829 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $156 | $1,246178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Belle Chasse
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
- Harold MillerHammond$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.